Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05171595
Other study ID # ST-Deviation WARD
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 20, 2018
Est. completion date June 9, 2020

Study information

Verified date January 2022
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study primarily aims to describe the frequency of significant ST-deviations, defined as ECG-ST-deviations <-0.255 or >0.245 mV for a minimum duration of 30 minutes as measured by a single-lead ECG in patients admitted with AECOPD or following major abdominal surgery. Secondarily we will describe the frequency of ST-deviations <-0.255 or >0.245 mV for a minimum duration of 1, 10 and 20 minutes, respectively, as well as for patients with ST-deviations <-0.1 or >0.1 mV for a minimum duration of 1, 10, 20 and 30 minutes, respectively. Lastly, we will investigate the association between ST-deviations and subsequent myocardial injury while adjusting for known risk factors.


Description:

Background: Assesment of wireless ECG-monitoring devices is essential for patient monitoring as it enables activity and out-of-hospital monitoring. Former studies have found a random variation for ST-deviations between wireless single-lead ECG and 12-lead ECG, which suggests that clinical monitoring of ST-deviations by single-lead ECG must be corrected for this to minimize false positive cases. Thus, we aimed to assess how a corrected limit of agreement for ST-deviations affects the ability to detect true myocardial ischemia by comparing thresholds to troponin elevations. Methods: This study sought to analyze data from two WARD cohort studies (NCT03491137) and (NCT03660501). Patients were included at Rigshospitalet and Bispebjerg Hospital from February 2018 to September 2020. The Surgery and COPD studies consisted of 505 and 202 patients, respectively, who were hospitalized with AECOPD or scheduled for elective major abdominal surgery lasting > 2 hours. All patients were monitored with wireless equipment, which continuously measured vital signs. The continuous wireless monitoring used in this study consisted of a single-lead ECG patch (Isansys Life Touch patch) which consists of two ECG electrodes placed on the left side of the patients' thorax. The patch measures respiratory rate (RR), heart rate (HR), heart rate variability (HRV) and electrocardiogram (ECG)s. Another monitoring device was the plasma concentration of high-sensitive cardiac troponin T (hsTnT, Cobas 8000, e801 module, Diagnostics Roche). In this study, patients were divided into a myocardial injury group with TnT elevations (of 20-64 ng/L with an absolute change of ≥ 5 ng/L, or a hsTnT level ≥65 ng/L, both evaluated as due to ischemic etiology) and a group with no myocardial injury. Analysis: Baseline characteristics of patients undergoing major abdominal surgery and patients admitted with AECOPD with and without myocardial injury will be summarized in frequency tables including Using descriptive statistics, we will describe the occurrence of ST-segment deviations in the single-lead (Lifetouch) ECG in patients with and without myocardial injury as well as the association between ST-deviation and subsequent myocardial injury, which will be adjusted for known risk factors; age, gender, BMI, daily smoker (never-, previous-, current smoker), alcohol consumption (none, below- or above recommendations), ASA classification (ASA 1,2,3,4), history of myocardial infarction, history of diabetes mellitus, history of chronic heart failure. Furthermore, the sensitivity and specificity of continuous wireless single-lead ECG with the applied threshold of <-0.255 mV and > 0.245 mV will be determined. Receiver operating characteristics (ROC) analyses will be made to determine which type of ST-deviation and which specific threshold value was most sensitive for TnT elevations. Through ROC analyses it will also be examined how different variations of durations affect the thresholds' sensitivity and specificity. Statistical analysis will be performed using statistical software SPSS.


Recruitment information / eligibility

Status Completed
Enrollment 698
Est. completion date June 9, 2020
Est. primary completion date June 9, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: WARD-COPD: - = 18 years - Patients admitted to emergency departments or pulmonary wards with AECOPD as admission diagnosis with suspected acute exacerbation of COPD - The diagnosis had to be sustained in the patient record at the time of inclusion - Expected admittance longer than 24 hours - Possibility of an investigator to include the patient within 24 hours from admission WARD-Surgery: - = 60 years - Elective major abdominal cancer surgery - Estimated surgical duration = 2 hours. Exclusion Criteria: WARD-COPD: - Patients who were not expected to cooperate to wear the monitoring equipment - Unable to give informed consent - Patients who were withheld active treatment - Implanted cardioverter defibrillator or pacemaker - Severe allergy for plaster/silicone WARD-Surgery: - Implanted cardioverter defibrillator or pacemaker - Allergy to study devices - Severe cognitive impairment assessed by MMSE - Inability to cooperate wearing the wireless monitoring equipment

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Lifetouch single-lead ECG monitoring
The continuous wireless monitoring is a single-lead ECG patch (Isansys Life Touch patch) which consists of two ECG electrodes placed on the left side of the patients' thorax. The patch measures respiratory rate (RR), heart rate (HR), heart rate variability (HRV) and electrocardiogram (ECG)s.
Diagnostic Test:
high-sensitive TnT measurements
Another monitoring device in the study was the plasma concentration of high-sensitive cardiac troponin T (hsTnT).

Locations

Country Name City State
Denmark Rigshospitalet, Department of Anesthesiology, Centre for Cancer and Organ Diseases, University of Copenhagen, Blegdamsvej 9, 2200 Copenhagen, Denmark Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency of patients with ST-deviation <-0.255 and/or >0.245 mV on single-lead ECG The primary outcome is the frequency of patients with ST-deviation <-0.255 and/or >0.245 mV (0.1 mV + LoA) on single-lead ECG monitoring lasting = 30 minutes. 30 minutes
Secondary Frequency of patients with significant ST-deviations <-0.1 and/or >0.1 mV lasting = 1 minute. 1 minute
Secondary Frequency of patients with significant ST-deviations <-0.1 and/or >0.1 mV lasting = 10 minutes. 10 minutes
Secondary Frequency of patients with significant ST-deviations <-0.1 and/or >0.1 mV lasting = 20 minutes. 20 minutes
Secondary Frequency of patients with significant ST-deviations <-0.1 and/or >0.1 mV lasting = 30 minutes. 30 minutes
Secondary Frequency of patients with ST-deviation <-0.255 and/or >0.245 mV lasting = 1 minute. 1 minute
Secondary Frequency of patients with ST-deviation <-0.255 and/or >0.245 mV lasting = 10 minutes. 10 minutes
Secondary Frequency of patients with ST-deviation <-0.255 and/or >0.245 mV lasting = 20 minutes. 20 minutes
Secondary Frequency of patients with ST-deviation <-0.255 and/or >0.245 mV lasting = 30 minutes and myocardial injury within three days of the first continuous monitoring day. 3 days
See also
  Status Clinical Trial Phase
Terminated NCT03940651 - Cardiac and Renal Biomarkers in Arthroplasty Surgery Phase 4
Completed NCT01688648 - Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft N/A
Completed NCT04794062 - Myocardial Injury and Quality of Life After COVID-19
Recruiting NCT04750616 - NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial Phase 2
Recruiting NCT04615871 - Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19 Phase 2
Completed NCT05691764 - Effect of Cyclosporine and Remote Ischemic Preconditioning in Reperfusion Ischemia Injury on Tetralogy Fallot Patients With Correction Surgery N/A
Withdrawn NCT04139655 - Colchicine Prevents Myocardial Injury After Non-Cardiac Surgery Pilot Study N/A
Completed NCT04436016 - PeRiOperaTivE CardioproTection With Ivabradine in Non-cardiac Surgery Phase 4
Completed NCT05748691 - Switching From Cardiac Troponin I to T
Completed NCT03338504 - Determining the Mechanism of Myocardial Injury and Role of Coronary Disease in Type 2 Myocardial Infarction
Recruiting NCT03013634 - Protective Effects of Dexmedetomidine on Myocardial Injury During Liver Transplantation N/A
Completed NCT00007358 - Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus N/A
Recruiting NCT05714618 - MR Evidence of Cardiac Inflammation Post-Stroke
Recruiting NCT04624503 - Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With COVID-19
Active, not recruiting NCT03339180 - Cardiac Injury in Patients With Influenza
Completed NCT03010839 - Cardiopulmonary Protective Effects of Modified Remote Ischaemic Preconditioning in Mitral Valve Replacement Surgery N/A
Recruiting NCT04743765 - HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial N/A
Enrolling by invitation NCT03253835 - Cardiac Blood Flow Patterns Associated With Left Ventricular Myocardial Damage
Completed NCT00817791 - Preconditioning With Hyperbaric Oxygen in Cardiovascular Surgery N/A
Completed NCT04149314 - The "Hypotension Prediction Index" in Patients Undergoing Lung Surgery N/A